255 related articles for article (PubMed ID: 26285571)
21. Clinically aggressive phenotype: A clinicopathological case series of atypical pituitary adenomas.
Lv L; Hu Y; Yin S; Wang M; Zhou P; Zhang N; Ma W; Zhang S; Jiang S
Clin Neurol Neurosurg; 2018 Apr; 167():93-98. PubMed ID: 29471288
[TBL] [Abstract][Full Text] [Related]
22. Multiregional sampling reveals a homogenous distribution of Ki-67 proliferation rate in pituitary adenomas.
Wolfsberger S; Kitz K; Wunderer J; Czech T; Boecher-Schwarz HG; Hainfellner JA; Knosp E
Acta Neurochir (Wien); 2004 Dec; 146(12):1323-7; discussion 1327-8. PubMed ID: 15480830
[TBL] [Abstract][Full Text] [Related]
23. p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions.
Thapar K; Scheithauer BW; Kovacs K; Pernicone PJ; Laws ER
Neurosurgery; 1996 Apr; 38(4):765-70; discussion 770-1. PubMed ID: 8692397
[TBL] [Abstract][Full Text] [Related]
24. Giant pituitary adenomas: pathologic-radiographic correlations and lack of role for p53 and MIB-1 labeling.
Madsen H; Borges TM; Knox AJ; Michaelis KA; Xu M; Lillehei KO; Wierman ME; Kleinschmidt-DeMasters BK
Am J Surg Pathol; 2011 Aug; 35(8):1204-13. PubMed ID: 21753697
[TBL] [Abstract][Full Text] [Related]
25. Pathobiology of pituitary adenomas and carcinomas.
Scheithauer BW; Gaffey TA; Lloyd RV; Sebo TJ; Kovacs KT; Horvath E; Yapicier O; Young WF; Meyer FB; Kuroki T; Riehle DL; Laws ER
Neurosurgery; 2006 Aug; 59(2):341-53; discussion 341-53. PubMed ID: 16883174
[TBL] [Abstract][Full Text] [Related]
26. Atypical pituitary adenomas: 10 years of experience in a reference centre in Portugal.
Tortosa F; Webb SM
Neurologia; 2016 Mar; 31(2):97-105. PubMed ID: 26300499
[TBL] [Abstract][Full Text] [Related]
27. [Significance of p53 protein expression and proliferative potential with MIB-1 on tumor recurrence of pituitary adenomas].
Miyagami M; Nakamura S
No To Shinkei; 1998 Jan; 50(1):27-32. PubMed ID: 9493195
[TBL] [Abstract][Full Text] [Related]
28. Clinicopathological correlates of extrasellar growth patterns in pituitary adenomas.
Sarkar S; Chacko AG; Chacko G
J Clin Neurosci; 2015 Jul; 22(7):1173-7. PubMed ID: 25979255
[TBL] [Abstract][Full Text] [Related]
29. Proliferation markers in different types of clinically non-secreting pituitary adenomas.
Schreiber S; Saeger W; Lüdecke DK
Pituitary; 1999 May; 1(3-4):213-20. PubMed ID: 11081200
[TBL] [Abstract][Full Text] [Related]
30. Early recognition of aggressive pituitary adenomas: a single-centre experience.
Ceccato F; Regazzo D; Barbot M; Denaro L; Emanuelli E; Borsetto D; Rolma G; Alessio L; Gardiman MP; Lombardi G; Albiger N; D'Avella D; Scaroni C
Acta Neurochir (Wien); 2018 Jan; 160(1):49-55. PubMed ID: 29170844
[TBL] [Abstract][Full Text] [Related]
31. Mdm2 and the p53 pathway in human pituitary adenomas.
Suliman M; Royds J; Cullen D; Timperley W; Powell T; Battersby R; Jones TH
Clin Endocrinol (Oxf); 2001 Mar; 54(3):317-25. PubMed ID: 11298083
[TBL] [Abstract][Full Text] [Related]
32. New WHO classification of pituitary adenomas (4th edition): assessment of pituitary transcription factors and the prognostic histological factors.
Nishioka H; Inoshita N
Brain Tumor Pathol; 2018 Apr; 35(2):57-61. PubMed ID: 29318396
[TBL] [Abstract][Full Text] [Related]
33. Plurihormonal PIT-1-Positive Pituitary Adenomas: A Systematic Review and Single-Center Series.
Andrews JP; Joshi RS; Pereira MP; Oh T; Haddad AF; Pereira KM; Osorio RC; Donohue KC; Peeran Z; Sudhir S; Jain S; Beniwal A; Chopra AS; Sandhu NS; Tihan T; Blevins L; Aghi MK
World Neurosurg; 2021 Jul; 151():e185-e191. PubMed ID: 33862299
[TBL] [Abstract][Full Text] [Related]
34. Association of Ki-67 Labelling Index and IL-17A with Pituitary Adenoma.
Glebauskiene B; Liutkeviciene R; Vilkeviciute A; Gudinaviciene I; Rocyte A; Simonaviciute D; Mazetyte R; Kriauciuniene L; Zaliuniene D
Biomed Res Int; 2018; 2018():7490585. PubMed ID: 29955610
[TBL] [Abstract][Full Text] [Related]
35. The Predictive Value of Pathologic Features in Pituitary Adenoma and Correlation with Pituitary Adenoma Recurrence.
Kim JS; Lee YS; Jung MJ; Hong YK
J Pathol Transl Med; 2016 Nov; 50(6):419-425. PubMed ID: 27713217
[TBL] [Abstract][Full Text] [Related]
36. ZAC1 and SSTR2 are downregulated in non-functioning pituitary adenomas but not in somatotropinomas.
Vieria Neto L; Wildemberg LE; Colli LM; Kasuki L; Marques NV; Moraes AB; Gasparetto EL; Takiya CM; Castro M; Gadelha MR
PLoS One; 2013; 8(10):e77406. PubMed ID: 24098585
[TBL] [Abstract][Full Text] [Related]
37. Clinicopathologic correlates of giant pituitary adenomas.
Chacko G; Chacko AG; Lombardero M; Mani S; Seshadri MS; Kovacs K; Scheithauer BW
J Clin Neurosci; 2009 May; 16(5):660-5. PubMed ID: 19285407
[TBL] [Abstract][Full Text] [Related]
38. Histone acetylation patterns of typical and atypical pituitary adenomas indicate epigenetic shift of these tumours.
Ebrahimi A; Schittenhelm J; Honegger J; Schluesener HJ
J Neuroendocrinol; 2011 Jun; 23(6):525-30. PubMed ID: 21453398
[TBL] [Abstract][Full Text] [Related]
39. Cytohistological correlation in pituitary tumor and immunological assessment with the help of Ki-67.
Sen A; Das C; Mukhopadhyay M; Mukhopadhyay S; Deb S; Mukhopadhyay B
J Postgrad Med; 2017; 63(2):96-99. PubMed ID: 27779153
[TBL] [Abstract][Full Text] [Related]
40. Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry.
Saeger W; Lüdecke DK; Buchfelder M; Fahlbusch R; Quabbe HJ; Petersenn S
Eur J Endocrinol; 2007 Feb; 156(2):203-16. PubMed ID: 17287410
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
